Changing the Conversation: Immunotherapy and Long-Term SurvivalVideo Categories: 2018 AONN Midyear, Immunotherapy, and Video Library
Dr Morganna Freeman discusses some of the ways immunotherapy has changed cancer care, including the expectation for long-term survival and how to treat patients in remission.
Hear Dr. Mesa discuss options available for individual patients who have failed hydroxyurea polycythemia vera.Supported through funding from Incyte
Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.